Instrument Inactif

Communiqués India Globalization Capital, Inc. NYSE

Actions

US45408X1000

Recherche biotechnologique et médicale

Cours en clôture NYSE Autres places de cotation
- ^USD	-

15/05	IGC Pharma, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
30/04	Les biotechs spécialisées dans le cannabis visent des IPO et un regain de financements privés après le reclassement américain	RE

Communiqués

02/07	IGC Pharma (NYSE: IGC) CEO and CFO Acquire More Than 4.2 Million Shares	AQ
30/06	MultiBagger MicroCaps IGC, RCT, PBK, HUMA, PRSO Stocks to Watch Now	AQ
23/06	IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow	AQ
11/06	IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis	AQ
09/06	Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts	AQ
02/06	IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis	AQ
19/05	IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment	AQ
15/05	IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference	AQ
14/05	Decoding Tau Heterogeneity: IGC Pharma Presents Novel Biomarker Research at the 2026 Global Tau Conference	PU
28/04	IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase	AQ
22/04	IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion	AQ
20/04	IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia	AQ
14/04	IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout	AQ
08/04	Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts	AQ
07/04	IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease	AQ
30/03	IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness	AQ
25/03	New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning	AQ
19/03	IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025	AQ
18/03	IGC Pharma : Annual Transition Report (Form 10-KT)	PU
18/03	IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026	AQ
03/02	IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation	AQ
10/12	IGC Pharma : Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.”	PU
19/08/25	IGC Pharma : FYE2025 Annual Meeting Proxy Card	PU
19/08/25	IGC Pharma : Notice & Access 2025 ASM	PU
19/08/25	IGC Pharma : DEFA 14A 08-18-25	PU